Yüklüyor......
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, includi...
Kaydedildi:
| Yayımlandı: | Leukemia |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6087717/ https://ncbi.nlm.nih.gov/pubmed/30030507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0210-1 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|